Zhang S, Li N, Sheng Y, Chen W, Ma Q, Yu X, et al. Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. Infect Agents Cancer. 2021;16(1):1–11.

Article  Google Scholar 

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13.

Article  CAS  PubMed  Google Scholar 

Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu TW, Lin HH, Wang LY. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2013;57(1):37–45.

Article  PubMed  Google Scholar 

Bai X, Chen L, Liu X, Tong Y, Wang L, Zhou M, et al. Adult hepatitis B virus vaccination coverage in China from 2011 to 2021: a systematic review. Vaccines. 2022;10(6):900.

Article  PubMed  PubMed Central  Google Scholar 

Wu J-W, Tseng T-C, Liu C-J, Su T-H, Liu C-H, Chen P-J, et al. Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. Adv Digest Med. 2021;8(4):211–7.

Article  Google Scholar 

Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.

Article  PubMed  Google Scholar 

Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–72.

Article  CAS  PubMed  Google Scholar 

Yu Z, Feng H, Zhuo Y, Li M, Zhu X, Huang L, et al. Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation. Cell Oncol. 2020;43(6):1129–45.

Article  CAS  Google Scholar 

Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79(6):665–74.

Article  CAS  PubMed  Google Scholar 

Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.

Article  PubMed  PubMed Central  Google Scholar 

Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

Article  CAS  PubMed  Google Scholar 

Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.

Article  CAS  PubMed  Google Scholar 

Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172.

Article  CAS  PubMed  Google Scholar 

Gladu P, Patterson G, Wikfors G, Chitwood D, Lusby W. The occurrence of brassicasterol and epibrassicasterol in the Chromophycota. 1990.

Vanmierlo T, Popp J, Koelsch H, Friedrichs S, Jessen F, Stoffel-Wagner B, et al. The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease. Acta Psychiatr Scand. 2011;124(3):184–92.

Article  CAS  PubMed  Google Scholar 

Additives EPoF, Food NSat. Scientific Opinion on the safety of stigmasterol‐rich plant sterols as food additive. EFSA J. 2012;10(5):2659.

Yazawa Y, Ikarashi N, Hoshino M, Kikkawa H, Sakuma F, Sugiyama K. Inhibitory effect of ergosterol on bladder carcinogenesis is due to androgen signaling inhibition by brassicasterol, a metabolite of ergosterol. J Nat Med. 2020;74(4):680–8.

Article  CAS  PubMed  Google Scholar 

Xu Y, Ryu S, Lee Y-K, Lee H-J. Brassicasterol from edible aquacultural Hippocampus abdominalis exerts an anti-cancer effect by dual-targeting AKT and AR signaling in prostate cancer. Biomedicines. 2020;8(9):370.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hassan ST. Brassicasterol with dual anti-infective properties against HSV-1 and Mycobacterium tuberculosis, and cardiovascular protective effect: nonclinical in vitro and in silico assessments. Biomedicines. 2020;8(5):132.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu P, Lou D, Qi L, Chen Z. The novel antiviral properties of brassicasterol against human adenovirus. Futur Virol. 2021;16(9):591–600.

Article  CAS  Google Scholar 

Hu K, Fu M, Wang J, Luo S, Barreto M, Singh R, et al. HSV-2 infection of human genital epithelial cells upregulates TLR9 expression through the SP1/JNK signaling pathway. Front Immunol. 2020;11.

Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006;38(3):200–11.

Article  CAS  PubMed  Google Scholar 

Song M, Bode AM, Dong Z, Lee M-H. AKT as a therapeutic target for cancerchallenging cancer therapy by targeting AKT. Can Res. 2019;79(6):1019–31.

Article  CAS  Google Scholar 

Testoni B, Levrero M, Zoulim F, editors. Challenges to a cure for HBV infection. Seminars in Liver Disease; 2017: Thieme Medical Publishers.

Ou D-P, Yang L-Y, Huang G-W, Tao Y-M, Ding X, Chang Z-G. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gastroenterol: WJG. 2005;11(14):2061.

Article  PubMed  PubMed Central  Google Scholar 

Llovet J, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

Article  PubMed  Google Scholar 

Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, et al. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol: WJG. 2013;19(40):6834.

Article  PubMed  PubMed Central  Google Scholar 

Lian J, Zou Y, Huang L, Cheng H, Huang K, Zeng J, et al. Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-κB signaling pathway in liver cancer. Oncol Lett. 2020;19(3):2043–52.

CAS  PubMed  PubMed Central  Google Scholar 

Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80–91.

Article  CAS  PubMed  Google Scholar 

Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88.

Article  CAS  PubMed  Google Scholar 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

Article  PubMed  Google Scholar 

Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005;41(2):307–14.

Article  CAS  PubMed  Google Scholar 

Macek Jilkova Z, Kurma K, Decaens T. Animal models of hepatocellular carcinoma: the role of immune system and tumor microenvironment. Cancers (Basel). 2019;11(10).